AZN Tozorakimab: 34% COPD Exacerbation Cut, $5B Peak

Investors buried the IL-33 class in 2025. Sanofi and Regeneron ran the AERIFY program for itpekimab, an anti-IL-33 antibody, and walked away when one of the two Phase 3 trials posted a 2% exacerbation benefit. The read-through was that IL-33 was a dead mechanism in COPD, a disease that had already eaten a dozen biologic failures. AstraZeneca just published full Phase 3 data that says otherwise. Tozorakimab cut moderate and severe COPD exacerbations by 29% to 34% across the entire enrolled population, including patients Dupixent cannot touch. The stock barely matters here. The franchise does.

The data that resurrected the mechanism

OBERON and TITANIA were replicate Phase 3 trials totaling 2,306 patients with symptomatic COPD and a history of at least two moderate or one severe exacerbation in the prior year. Patients got tozorakimab 300 mg once every four weeks or placebo on top of inhaled standard of care for 52 weeks. The primary endpoint was the annualized rate of moderate to severe exacerbations in former smokers.

Tozorakimab hit it cleanly. OBERON showed a 29% reduction in the former-smoker primary population and 30% in the overall population. TITANIA showed 34% in former smokers and 29% overall. The pooled subgroup analysis is the part that matters for the commercial story: patients with blood eosinophils below 150 achieved a 23% reduction, those at or above 150 achieved 34%, and those at or above 300 achieved 43%. The benefit held across smoking status and across every stage of lung function severity. The only adverse drug reaction was injection-site reaction.

This is not a marginal signal. A 30% reduction in exacerbations is roughly double what the failed IL-33 program produced, and it arrives in a disease where exacerbations are the event that kills. Only half of COPD patients live more than 3.5 years after their first severe exacerbation, and the disease drives more than 2,500 emergency department visits per day in the US alone.

The eosinophil threshold is the whole thesis

Dupixent (dupilumab) was the first biologic approved for COPD in September 2024, and its label is gated. It covers roughly 300,000 US adults with inadequately controlled COPD and an eosinophilic phenotype, which in practice means a blood eosinophil count at or above 300. That restriction exists because Dupixent’s Phase 3 BOREAS and NOTUS data did not separate from placebo in patients below the threshold. Sanofi and Regeneron built the first COPD biologic around the roughly one-third of patients with type 2 inflammation.

Tozorakimab wins in the other two-thirds. The 23% reduction in the sub-150 eosinophil group is the number no prior biologic has been able to produce. That is the difference between a $3 billion drug and a $5 billion drug. AstraZeneca raised its peak sales forecast for tozorakimab from $3 billion to more than $5 billion when it reported second-quarter results, and CEO Pascal Soriot told CNBC the number could go higher “simply because the unmet need is huge.” A drug that works across the full eosinophil range is not competing with Dupixent for a niche. It is expanding the addressable market for biologics in COPD by a factor of three.

The mechanism explains why. Tozorakimab inhibits the signaling of both the reduced and oxidized forms of IL-33, which AstraZeneca argues lets it both reduce inflammation and break the mucus dysfunction cycle that drives worsening. The ERS presentation included an integrated analysis showing tozorakimab reduced lung mucus plug scores, the first biologic to do so in a broad COPD population. That dual pharmacology is the specific difference from itpekimab, which targeted a narrower slice of the pathway. See the Sanofi pipeline piece for the full account of why AERIFY failed and why the mechanism looked dead.

Where the $5 billion fits in a $243 billion company

AstraZeneca closed at $156.94 with a $243.4 billion market cap. Full-year 2025 revenue was $58.7 billion, up 8% at constant exchange rates. A $5 billion peak-sales drug is roughly 8.5% of current revenue. That is not a rounding error. It is the largest respiratory product in the portfolio and a core plank of the $80 billion 2030 revenue target the company has set for itself.

But be precise about what this data changes. Tozorakimab’s top-line result was already reported in March, and AstraZeneca already raised the peak-sales forecast in July. The full NEJM publication confirms the number rather than discovering it. The stock has not been waiting for this readout to move. The real question is whether the FDA Priority Review, which has an accepted BLA but no firm PDUFA date yet, converts cleanly. The data says it should. The broad-population claim, if the FDA grants it, is the competitive advantage no other COPD biologic would hold at launch.

The respiratory franchise is already the growth engine. Breztri crossed $1 billion in annual sales in 2025 and now carries a second approval in asthma. Fasenra anchors the severe-asthma biologics franchise. Tozorakimab slots in as the COPD asset that ties it together. The broader respiratory shelf is covered in the respiratory catalysts ranking, but the short version is that no other company has a COPD biologic with an all-comers efficacy profile.

Risks

The regulatory claim is the risk that matters. The FDA has never approved a COPD biologic for the broad, non-eosinophilic population. The agency could confine the label to the eosinophil-high group where the effect is cleanest, which would cut the addressable market back toward Dupixent’s territory and trim the $5 billion number. The 23% benefit in the sub-150 group, while clinically meaningful, is the softest of the subgroup results and the most likely place for label negotiation.

Then there is safety, which has killed every prior attempt at a broad COPD biologic. Riociguat’s PH-ILD trial was terminated early for increased hospitalization and mortality in a different pulmonary disease, and the class as a whole carries a tarnished record. Tozorakimab’s safety profile here is clean, with injection-site reaction as the only adverse drug reaction, but a one-year trial in a disease that kills over a 3.5-year horizon leaves durability unanswered.

Further out, AstraZeneca’s own capital allocation adds another risk. The company has been rumored in merger talks with Bristol Myers Squibb twice this year, and both times the reports were denied. A $200 billion-plus megadeal would reframe the entire equity story around integration risk rather than pipeline execution. The tozorakimab thesis survives a deal, but the valuation does not.

Verdict

AstraZeneca is not a buy on tozorakimab alone. A $5 billion peak-sales drug on a $243 billion stock is worth maybe a few points of multiple, and the top-line has been public since March. What matters, for an AZN holder, is the confirmation that the respiratory R&D engine still works after the Ultomiris HSCT-TMA miss earlier this year. Tozorakimab validates the company’s bet that targeting the top of the inflammatory cascade works in COPD where the middle of it did not.

This is also a direct rebuke to Sanofi’s decision to abandon the lane. Sanofi owned the anti-IL-33 mechanism through itpekimab, saw a split Phase 3 result, and walked away rather than spend another three years and a billion dollars chasing a broad-population claim. AstraZeneca ran the replicate trials, got the consistent result, and is now the only company with a biologic that works across the full eosinophil range. The lesson is not that IL-33 works. The lesson is that replicate trials and a broad enough enrollment are what separate a franchise from a footnote, and AstraZeneca was the one willing to pay for both.

The tradeable read-through is actually negative for Sanofi, which ceded the IL-33 lane and now watches AstraZeneca build the broad-population COPD biologic it abandoned. The $5 billion number is real, the mechanism is resurrected, and the only open question is whether the FDA grants the all-comers label. The bet is it does, because the pooled subgroup data is consistent enough that a broad claim is defensible. Hold AZN for the franchise, and treat a clean Priority Review approval as confirmation, not a catalyst.

NEJM, OBERON and TITANIA · ClinicalTrials.gov: OBERON